Active Surveillance

Home » Treatments » Active Surveillance

Gleason 6 Is Bogus Prostate Cancer

Noted urologic surgeon Bert Vorstman, MD, MS, FAAP, FRACS, FACS today has issued a stinging report regarding the unreliable PSA test, the mislabeling of the common Gleason 6 prostate disease as a cancer, and the misrepresentation that the radical (robotic) prostatectomy treatment is scientifically proven to be safe and effective – a charade that represents an outrageous and shameful trifecta of abominations. Read the article.

Active Surveillance for Intermediate Risk Prostate Cancer: Survival Outcomes in the Sunnybrook Experience.

Data from the survival outcomes of patients support the use of active surveillance in low risk and intermediate risk cases of Gleason 6 but not Gleason 7 prostate cancer. Multiparametric magnetic resonance imaging and novel biomarkers might be vital in detecting favorable Gleason 7 disease. Read the article here.

Active Surveillance

Predicting outcomes on active surveillance for intermediate-risk patients Read the article here. Active Surveillance for Intermediate-risk Prostate Cancer Challenged Read the article here. Active Surveillance versus Watchful Waiting Read the article here. Surgery isn’t necessarily best for prostate cancer, according to study led by Minneapolis VA Read the article here.

Scroll to Top